Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Opus Genetics, Inc.'s SEC filings document financing, governance, capital-structure and operating disclosures for a Delaware clinical-stage biopharmaceutical company developing ophthalmic gene therapies. Form 8-K reports cover senior secured notes, preferred stock private placement activity, financial results, corporate presentations and compensatory arrangements.
Proxy materials and stockholder-vote reports cover director elections, auditor ratification, say-on-pay matters and amendments affecting authorized common stock. The filings also record corporate updates related to the company's inherited retinal disease pipeline and Phentolamine Ophthalmic Solution 0.75%.
Opus Genetics, Inc. filed a Form S-8 on September 26, 2025 to register securities under its 2020 Equity Incentive Plan. The filing incorporates by reference the company’s 2024 Annual Report (filed March 31, 2025), subsequent quarterly reports (filed May 15, 2025 and August 13, 2025) and multiple current reports filed between January 7, 2025 and September 2, 2025. The Registration Statement relies on prior effective S-8 registrations and includes customary exhibits and a power of attorney signed by management and directors.